Day: January 20, 2022

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global...

First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in...

error: Content is protected !!